Compounds > colletochlorin b

Page last updated: 2024-11-11

colletochlorin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

colletochlorin B: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	6439644
CHEMBL ID	4294528
SCHEMBL ID	1527059
MeSH ID	M0157673

Synonyms (12)

Synonym
benzaldehyde, 3-chloro-5-(3,7-dimethyl-2,6-octadienyl)-4,6-dihydroxy-2-methyl-, (e)-
83324-48-5
3-chloro-5-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-4,6-dihydroxy-2-methylbenzaldehyde
colletochlorin b
5-chloro-3-[(2e)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxy-6-methylbenzaldehyde
3W54
SCHEMBL1527059
Q27465081
UEUMAXMCCDEOIJ-XYOKQWHBSA-N
CHEMBL4294528 ,
bdbm50464455
AKOS040751240

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
" In this study, we purified and characterised recombinant MpAOX in dose-response assays with activators and inhibitors, followed by a kinetic characterization both in an aqueous environment and in physiologically-relevant proteoliposomes."	( Biochemical characterization and inhibition of the alternative oxidase enzyme from the fungal phytopathogen Moniliophthora perniciosa. Baroni, RM; Barsottini, MRO; Copsey, A; Cordeiro, AT; Moore, AL; Pereira, GAG; Young, L, 2020)	0.56

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Alternative oxidase, mitochondrial	Trypanosoma brucei brucei	IC50 (µMol)	0.0030	0.0020	1.4845	5.9300	AID1401088
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay ID	Title	Year	Journal	Article
AID1866142	Antibacterial activity aginst Bacillus subtilis DSM 10 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID1866157	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID1401092	Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for growth inhibition of Trypanosoma brucei brucei Lister 427	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase.
AID1866147	Antifungal activity against Mucor hiemalis DSM 2656 assessed as inhibition of fungal growth incubated for overnight by serial dilution method
AID1401091	Cytotoxicity against human HepG2 cells after 96 hrs by CCK8 assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase.
AID1866160	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID1401088	Inhibition of recombinant His-tagged and SUMO-tagged Trypanosoma alternative oxidase expressed in Escherichia coli Rosetta2 using 1-ubiquinol as substrate measured over 6 mins by spectrophotometric method	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase.
AID1401090	Mixed type non-competitive inhibition of recombinant His-tagged and SUMO-tagged Trypanosoma alternative oxidase expressed in Escherichia coli Rosetta2 at 1 to 10 nM using varying levels of 1-ubiquinol as substrate measured over 6 mins by spectrophotometri	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase.
AID1866158	Cytotoxicity against human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID1866153	Antibacterial activity against Staphylococcus aureus DSM 346 assessed as inhibition of bacterial growth incubated for overnight by serial dilution method
AID1866155	Cytotoxicity against human KB 3-1 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID1866159	Cytotoxicity against human A-431 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID1866156	Cytotoxicity against human PC-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID1401089	Growth inhibition of Trypanosoma brucei brucei Lister 427 assessed as reduction in ATP levels after 48 hrs by CellTiter-Glo assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase.
AID1866154	Cytotoxicity against mouse L929 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2013	Proceedings of the National Academy of Sciences of the United States of America, Mar-19, Volume: 110, Issue:12	Structure of the trypanosome cyanide-insensitive alternative oxidase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (16.67)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (50.00)	24.3611
2020's	2 (33.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.38 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.32 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.38)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
puromycin [no description available]	2.15	1	0	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor
ascofuranone ascofuranone: structure. ascofuranone : A dihydroxybenzaldehyde that is 2,4-dihydroxybenzaldehyde which is substituted by a (2E,6E)-7-[(2S)-5,5-dimethyl-4-oxotetrahydrofuran-2-yl]-3-methylocta-2,6-dien-1-yl group at position 3, chlorine at position 5, and a methyl group at position 6. A meroterpenoid produced by the soil fungus, Acremonium sclerotigenum. It is a promising drug candidate against the tropical disease, African trypanosomiasis.	2.15	1	0	dihydroxybenzaldehyde; meroterpenoid; monochlorobenzenes; olefinic compound; resorcinols; sesquiterpenoid; tetrahydrofuranone	angiogenesis inhibitor; antilipemic drug; antineoplastic agent; antiprotozoal drug; fungal metabolite
ubiquinol ubiquinol: reduced forms of ubiquinone; see also record for ubiquinol 10. ubiquinol-10 : A ubiquinol in which the polyprenyl substituent is decaprenyl.	2.1	1	0	polyprenylhydroquinone; ubiquinol	biomarker; metabolite
ubiquinone Ubiquinone: A lipid-soluble benzoquinone which is involved in ELECTRON TRANSPORT in mitochondrial preparations. The compound occurs in the majority of aerobic organisms, from bacteria to higher plants and animals.	2.1	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
African Sleeping Sickness [description not available]	0	2.15	1	0
Trypanosomiasis, African A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.	0	2.15	1	0
Granulocytic Leukemia [description not available]	0	1.97	1	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	0	1.97	1	0